ClinicalTrials.gg
CompletedNCT02622932Updated Apr 30, 2019

Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients

A Phase 1 interventional study of Anlotinib and 14C-labeled Anlotinib in Advanced Solid Tumors, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-04-30.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The purpose of this study is to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer patients.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is the lead sponsor of 320 studies on the registry; 76 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • signed and dated
  • or cytologically confirmed diagnosis of advanced solid tumor (including RCC、NSCLC、STS and CRC)
  • failed to the treatment of line 1 or 2
  • PS:0-1, of more than 3 months
  • main organs function is normal

Exclusion criteria

Exclusion Criteria:

  • prior treatment with Anlotinib or Allergic to drug or its formulation ingredients
  • subjects with the gastrointestinal tract, liver and kidney disease of affect drug absorption and metabolism
  • (4.0) Grade 1 or higher non-remission toxicity induced by any other previous treatments
  • patients with pleural effusion or ascites, causing respiratory syndrome (CTCAE Grade 2 or higher dyspnea [Grade 2 dyspnea refers to Shortness of breath with a small amount of activities, affecting Instrumental activities of daily life])
  • patients underwent major surgical treatment,open or significant traumatic injury within 28 days prior to assignment
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Anlotinib and 14C-labeled Anlotinib

    each participant will be given a single dose of 14C-labeled gilteritinib.

    Drug: Anlotinib and 14C-labeled Anlotinib

Interventions

  • DrugAnlotinib and 14C-labeled Anlotinib

    oral

06

What researchers measure

Primary outcomes

  1. Cumulative excretion of 14C-labeled Anlotinib (radioactivity in urine)

    Time frame: up to 10 Days(endpoint when the two consecutive time points of cumulative excretion <1%)

  2. Cumulative excretion of 14C-labeled Anlotinib (radioactivity in feces)

    Time frame: up to 10 Days(endpoint when the two consecutive time points of cumulative excretion <1%)

  3. Excretion rate of 14C-labeled Anlotinib (radioactivity in urine)

    Time frame: up to 10 Days(endpoint when the two consecutive time points of cumulative excretion <1%)

  4. Excretion rate of 14C-labeled Anlotinib (radioactivity in feces)

    Time frame: up to 10 Days (endpoint when the two consecutive time points of cumulative excretion <1%)

  5. Pharmacokinetics of 14C-labeled Anlotinib (Radioactivity in whole blood):Peak Plasma Concentration(Cmax)

    Peak Plasma Concentration(Cmax),Cmax in ng/mL,

    Time frame: up to 10 Days (endpoint when the two consecutive time points of blood drug concentration <150 DPM/mL)

  6. Pharmacokinetics of 14C-labeled Anlotinib (Radioactivity in whole blood):Peak time(Tmax)

    Peak time(Tmax),Tmax in h.

    Time frame: up to 10 Days (endpoint when the two consecutive time points of blood drug concentration <150 DPM/mL)

  7. Pharmacokinetics of 14C-labeled Anlotinib (Radioactivity in whole blood):Half life(t1/2)

    Half life(t1/2),t1/2 in h.

    Time frame: up to 10 Days (endpoint when the two consecutive time points of blood drug concentration <150 DPM/mL)

  8. Pharmacokinetics of 14C-labeled Anlotinib (Radioactivity in whole blood): Area under the plasma concentration versus time curve (AUC)

    Area under the plasma concentration versus time curve (AUC), AUC in ng.h/mL.

    Time frame: up to 10 Days (endpoint when the two consecutive time points of blood drug concentration <150 DPM/mL)

  9. Pharmacokinetics of 14C-labeled Anlotinib (Radioactivity in whole blood): Clearance(CL)

    Clearance(CL),CL in L/h.

    Time frame: up to 10 Days (endpoint when the two consecutive time points of blood drug concentration <150 DPM/mL)

Secondary outcomes

  1. Metabolite identification of Anlotinib in plasma, urine and feces

    Time frame: up to 10 Days(endpoint when the two consecutive time points of cumulative excretion <1%)

07

Study locations

1 site
  • Jiangsu Province Hospital
    Nanjing, Jiangsu 210029, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2015 to primary completion in Dec 2016, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2015
First posted
Dec 7, 2015
StartActual
Dec 2, 2015
Primary completionActual
Dec 30, 2016
CompletionActual
Aug 2017
Last update
Apr 30, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02622932
Responsible party
Sponsor
First posted
Dec 7, 2015
Start date
Dec 2, 2015
Primary completion
Dec 30, 2016
Completion
Aug 2017
Last update
Apr 30, 2019

Study contacts

Lihua Bao, Doctor
study director · The First Affiliated Hospital with Nanjing Medical University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion